Regular ArticlePrognostic Factors in Extraovarian Primary Peritoneal Carcinoma☆
References (41)
Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary: case report
Am J Obstet Gynecol
(1959)- et al.
Papillary tumors of the peritoneum in women: mesothelioma or papillary carcinoma
Am J Obstet Gynecol
(1977) - et al.
Primary papillary serous neoplasia of the peritoneum: a clinico-pathologic and ultrastructural study of eight cases
Hum Pathol
(1989) - et al.
Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases
Hum Pathol
(1990) - et al.
Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma
Gynecol Oncol
(1993) - et al.
Epidemiological difference among women with extra-ovarian primary peritoneal carcinoma and women with primary epithelial ovarian cancer
Obstet Gynecol
(1998) - et al.
Peritoneal papillary carcinoma
Gynecol Oncol
(1988) - et al.
Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary
Gynecol Oncol
(1993) - et al.
Primary clear cell carcinoma of the peritoneum
Gynecol Oncol
(1991) - et al.
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin–doxorubicin–cyclophosphamide or paclitaxel–cisplatin
Gynecol Oncol
(1997)
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIC serous cystadenocarcinoma of the ovary
Gynecol Oncol
The ovarian mesothelioma
Am J Obstet Gynecol
Multifocal extraovarian serous carcinoma: a histochemical and immunohistochemical study
Eur J Gynecol Oncol
Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases
Int J Gynecol Pathol
Serous surface papillary carcinoma: a clinicopathologic study of 10 cases and comparison with stage III–IV ovarian serous carcinoma
Am J Surg Pathol
Multiple focal extraovarian serous carcinoma
Int J Gynecol Pathol
A case-matched comparison of extraovarian versus primary ovarian adenocarcinoma
Cancer
Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases
Cancer
Papillary serous carcinoma of the peritoneum
Obstet Gynecol
Papillary serous adenocarcinoma of the peritoneum
Cancer
Cited by (76)
Primary peritoneal serous carcinoma: a primer for radiologists
2022, Clinical ImagingCitation Excerpt :PPSC has been demonstrated to have a poor prognosis similar to or even worse than that of advanced serous ovarian carcinoma.5 Median overall survival is typically reported in the range of 21 to 23.5 months, though this value is prone to large fluctuations across studies due to small sample sizes.6–8 Treatment of PPSC typically mirrors that of stage III/IV ovarian carcinoma, which includes surgical debulking and chemotherapy, as similar response rates between the two have been demonstrated.9,10
Diseases of the Peritoneum
2020, Gynecologic Pathology, Second EditionClinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience
2019, European Journal of Surgical OncologyCitation Excerpt :Diagnosing SPPC is a challenge as, most patients, present with diffuse peritoneal spread without any apparent disease in the ovaries. This is seen in 10–20% cases wherein the diagnosis is SPPC and not epithelial ovarian carcinoma (EOC) [3–5]. In the absence of established standard treatment, serous papillary peritoneal carcinoma patients have been managed with cytoreductive/debulking surgery and platinum and taxane based chemotherapy, similar to epithelial ovarian cancer [6,7].
Epithelial ovarian cancer
2018, Clinical Gynecologic OncologyAn 18 year population-based study on site of origin and outcome of patients with peritoneal malignancy in Ireland
2017, European Journal of Surgical Oncology
- ☆
Benda, J, AZaino, R
- 1
To whom correspondence and reprint requests should be addressed at present address: Gynecologic Oncology, University of Vermont, MCHV Campus, Shepardson 330, 111 Colchester Avenue, Burlington, VT 05401-1429. Fax: 802-656-2360. E-mail:[email protected].